



Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

8 May 2026

**Notice under section 708A(5)(e) of the *Corporations Act 2001*
Telix Pharmaceuticals Limited (ASX Code: TLX) (“Company”)**

Reference is made to the Appendix 2A released on 8 May 2026 and the issue of fully paid ordinary shares in Telix Pharmaceuticals Limited (**Shares**). For the purposes of section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**), the Company gives notice that:

- (a) The Company issued 264,943 Shares on 8 May 2026 in satisfaction of a US\$4 million deferred payment for the acquisition of ImaginAb, Inc. (refer to the Company’s ASX announcements dated 13 and 31 January 2025 for further details).
- (b) The Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act.
- (c) As at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and sections 674 and 674A of the Corporations Act.
- (d) As at the date of this notice, there is no information that is “excluded information” (as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.

Authorised for release by

A handwritten signature in black ink, appearing to read "Shomalin Naidoo".

Shomalin Naidoo
Company Secretary (interim)